OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies
Summary
Among its key subsidiaries, OSR is advancing Vaximm, a Swiss-based biotech developing a novel GBM vaccine (VXM01) aimed at enhancing immune response against glioblastoma. "Glioblastoma remains one of the most challenging cancers, and we anticipate that establishing this financing facility will enable us to advance our Vaximm immunotherapy platform and other innovative healthcare solutions. Innovate GBM unites scientists, clinicians, investors, patient advocates, and regulatory experts, creating an interconnected community that streamlines collaboration, amplifies resources, and accelerates investment into glioblastoma R&D. OSRs vision is to acquire and operate a portfolio of innovative healthcare companies, improving patient care through cutting-edge research and development. For more information, visit www.OSR-Holdings.com.Innovate GBM is a 501(c)(3) nonprofit organization dedicated to expanding the glioblastoma ecosystem by uniting researchers, investors, clinicians, and patient advocates.